Pernix Therapeutics upgraded at Needham As previously reported, Needham upgraded Pernix to Strong Buy from Buy. The analyst said Pernix's purchase of Treximet is a "game changer" and should increase short-term profitability and provides an anchor in the CNS market. Price target raised to $10 from $9.
News For PTX From The Last 14 Days
Check below for free stories on PTX the last two weeks.